GemPharmatech (SH:688046) Zhong Guo Jin Rong Xin Xi Wang·2025-12-11 07:34Core Viewpoint - Chengdu Yaokang's second-phase project will enhance its core advantages in genetic engineering and support the development of innovative pharmaceutical companies in the western region of China [1][4]. Company Summary - Chengdu Yaokang Biotechnology Co., Ltd. is a wholly-owned subsidiary of Jiangsu Jicui Yaokang Biotechnology Co., Ltd., established in August 2018 in Chengdu. The first phase of the project received production approval in November 2020, focusing on "gene editing models + drug efficacy screening" to provide foundational services for innovative pharmaceutical companies [4][6]. - The successful launch of the second-phase project marks a significant step in building animal model platforms, extending service capabilities to pharmacology, toxicology, and GLP safety evaluations [6]. Industry Summary - Chengdu Yaokang has established or co-built several provincial key laboratories and resource-sharing service platforms at various administrative levels. The second-phase project will deepen disease model research and technical service systems, integrating resources across the biopharmaceutical industry [6]. - A strategic cooperation agreement was signed between Chengdu Medical College and Chengdu Yaokang, focusing on the development of a key laboratory for aging mechanisms and interventions. This collaboration aims to leverage both parties' strengths to promote high-quality development in the regional biopharmaceutical industry and accelerate the transformation of scientific research achievements [9]. - Chengdu Medical City has been a key player in the development of innovative pharmaceuticals for over a decade, currently housing over 650 health enterprises. The city aims to optimize the business environment and enhance the industrial ecosystem to attract more innovative pharmaceutical companies [9].